Cue Biopharma Inc
Company Overview
Cue Biopharma is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer and autoimmune diseases. The company's proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells), is designed to selectively engage and modulate targeted T cells within a patient's body.
The company focuses on developing biologics that selectively target and modulate disease-relevant T cell subsets for treating cancer and autoimmune diseases. Their lead program, CUE-101, is in clinical development for the treatment of HPV+ cancers.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $3.34m | $12.34m | - | $188000.0 | 0.00% | 1.52% |
| June 30, 2024 | $2.66m | $13.26m | - | $215000.0 | 0.00% | 1.62% |
| March 31, 2024 | $1.72m | $14.63m | - | $241000.0 | 0.00% | 1.65% |
Company Impact
Help us evaluate Cue Biopharma Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.